xaracoll Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xaracoll, and when can generic versions of Xaracoll launch?
Xaracoll is a drug marketed by Innocoll Pharms and is included in one NDA. There are two patents protecting this drug.
This drug has eighty patent family members in twenty-three countries.
The generic ingredient in XARACOLL is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xaracoll
A generic version of xaracoll was approved as bupivacaine hydrochloride by HOSPIRA on February 17th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for xaracoll?
- What are the global sales for xaracoll?
- What is Average Wholesale Price for xaracoll?
Summary for xaracoll
International Patents: | 80 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 125 |
Clinical Trials: | 4 |
Patent Applications: | 4,616 |
What excipients (inactive ingredients) are in xaracoll? | xaracoll excipients list |
DailyMed Link: | xaracoll at DailyMed |
Recent Clinical Trials for xaracoll
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Premier Research Group plc | Phase 3 |
Cmed | Phase 3 |
Innocoll | Phase 3 |
US Patents and Regulatory Information for xaracoll
xaracoll is protected by two US patents.
Patents protecting xaracoll
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Innocoll Pharms | XARACOLL | bupivacaine hydrochloride | IMPLANT;IMPLANTATION | 209511-001 | Aug 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for xaracoll
See the table below for patents covering xaracoll around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 3536748 | ⤷ Sign Up | |
Eurasian Patent Organization | 027745 | МОДИФИЦИРОВАННЫЙ КОЛЛАГЕН (MODIFIED COLLAGEN) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2013104687 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |